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 2 
Introduction 
 
In the United States (US), the problem of non-medical use of prescription opioids (PO) 
has emerged as a major public health issue [2]. Other countries, such as Australia, New 
Zealand [12], and Canada [33], also are concerned about the phenomenon of PO abuse. 
In the US, oxycodone and hydrocodone are among the most commonly prescribed or 
regularly used opioid, as well as the most commonly diverted PO analgesics [5, 25]. 
These data have indicated that PO abuse has steadily increased among heroin and 
recreational polydrug users since 2000 [5]. An additional concern related to the 
increased use of PO is opioid overdose, which increased in the US from the mid-1990s 
to the present time [11, 10] and recently became a leading cause of accidental death in 
the US [1]. Thus, the risks of PO abuse and overdose make physicians reluctant to 
prescribe POs in general, and access to adequate pain management in drug users in 
particular is becoming increasingly difficult [39, 20]. In those patients who are prescribed 
POs for pain relief, misuse may occur in pain patients with no history of opioid abuse 
who become dependent on the medications for their reinforcing properties, whether 
good drug effects or relief of anxiety or mood symptoms, or misuse may occur in drug-
seeking individuals with pre-existing opioid abuse histories. Thus, balancing the need for 
effective pain relief and reducing the risks of opioid abuse and overdose remains a 
challenge for public health policy [7].  
In this context of easy access to opioid analgesics for the general population, opioid 
overdoses due to diversion [8] and difficulties in accessing treatment for pain and opioid 
dependence, expanding access to a less risky treatment for pain and opioid dependence 
is a logical and plausible public health response.  
For decades, buprenorphine, a partial mu-opioid agonist, has been used to treat acute 
and chronic pain [16]. More recently, a sublingual formulation of buprenorphine has been 
used to treat opioid dependence [38] in both substance abuse treatment clinics and in 
primary care settings [18]. Although sublingual buprenorphine is not approved by the 
FDA for treating pain, some have suggested its use in the management of concurrent 
pain and opioid dependence [23]. However, few studies have systematically examined 
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whether buprenorphine maintenance alters prescription opioid abuse in this population. 
Thus, assessment of the effectiveness of buprenorphine in treating pain and also 
reducing the abuse liability of oxycodone would be relevant to the public health problem 
of PO abuse. In the current study, patients with chronic, non-malignant pain who were 
abusing their prescription opioid medications were maintained on different doses of 
sublingual buprenorphine/naloxone (2/0.5, 8/2, and 16/4 mg per day in divided doses) 
and given the opportunity to self-administer oxycodone in a laboratory setting.  
 
Methods 
 
Participants 
All of the participants were currently under the care of a physician for mild to moderate 
chronic, non-malignant pain. They were also required to meet DSM-IV criteria for opioid 
dependence, but were not seeking treatment for their opioid dependence. Potential 
participants were excluded from the study if they had a current major Axis I 
psychopathology other than opioid dependence (i.e. schizophrenia or bipolar disorder) or 
met DSM-IV criteria for dependence on drugs other than opioids, nicotine or caffeine or 
had a primary diagnosis of neuropathic pain, malignant pain, headache, or chronic lower 
back pain with failed surgeries. Current buprenorphine maintenance and history of failed 
treatment with buprenorphine maintenance for pain also were exclusionary. 
 
Data Collection 
After completing an initial telephone interview, eligible participants came into the 
laboratory to provide consent to receive additional screening, which included completing 
detailed medical history and drug use questionnaires, interviews with a psychologist and 
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psychiatrist, and a medical evaluation conducted by a physician. Prescription opioid use 
was ascertained in multiple ways (self-report, verification with prescribing physician, 
and/or presentation of prescription opioid bottles) and was converted to number of 
morphine equivalents used per day. We also collected sociodemographic data such as 
age, gender, ethnicity, education and employment. Urine drug toxicologies (using urine 
quick tests) also were performed several times during screening to test for opioids, 
benzoylecgonine (cocaine metabolite), benzodiazepines, cannabinoids and 
amphetamines. During laboratory sessions, subjective responses were measured and 
reinforcing effects of oxycodone were assessed, as described below. 
 
Study Design 
This study was described in detail in a previous paper that presented preliminary results 
[17]. Individuals who met the eligibility criteria were admitted to an inpatient research unit 
for 7 weeks and transitioned from their baseline prescription opioid to 
buprenorphine/naloxone combination (Bup/Nx). During the first week after admission, 
participants were withdrawn from their previous opioid analgesic regimen and stabilized 
on one of three doses of Bup/Nx (2/0.5, 8/2, or 16/4 mg/day). The total daily Bup/Nx 
dose was administered QID in equal divided doses throughout the day (Figure 1). 
Participants were treated for emergent withdrawal symptoms with various supplemental 
medications until withdrawal symptoms dissipated based on self-report and observer 
ratings. Patients were maintained on each Bup/Nx dose for approximately 2 weeks: 1 
week of stabilization followed by 1 week of laboratory testing. Each participant received 
all three Bup/Nx doses in random order under double-blind conditions. 
 
Reinforcing Effects 
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During each maintenance period, participants could self-administer oral oxycodone (0, 
10, 20, 40 or 60 mg) during separate laboratory sessions. Each laboratory day consisted 
of two types of sessions, a sample session during which participants were provided with 
one of the possible doses of drug (oxycodone) and US$20, and a self-administration 
(choice) session that occurred a few hours later on the same day. During the sample 
session, the subjective, physiological, and analgesic effects of oxycodone were 
measured. During the choice session, participants could self-administer the dose of 
oxycodone that was given during the sample session or receive money.  Participants 
then completed a self-administration task to receive portions of the dose of drug or 
money they sampled (0–100% in increments of 10%). For each 10% increment of drug 
or money, participants were required to complete an increasing number of finger presses 
on a computer mouse (50, 100, 200, 400, 800, 1200, 1600, 2000, 2400, 2800). 
Immediately following the self-administration task, money and/or the total amount of drug 
earned during the task was administered. The sample session began at approximately 
11 am and the choice session began at approximately 3 pm (Figure 1). 
 
Subjective Effects  
All of the questionnaires used in this study were described in our previous article [17]. 
For the present analysis, opioid withdrawal symptoms and clinical pain were measured 
after administration of the first daily Bup/Nx maintenance dose. Subjective symptoms of 
opioid withdrawal were assessed with the Subjective Opioid Withdrawal Scale (SOWS; 
range: 0-64 [9]). Clinical pain assessment was made using the 15-item Short-form McGill 
Pain Questionnaire [26] based on their general pain condition while maintained on 
Bup/Nx. Clinical pain was also assessed with the MPQ at the first screening visit prior to 
initiation of Bup/Nx maintenance. 
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Statistical analyses 
For the present analysis, we used only a subset of the dependent variables collected 
during the study because of our focused interest in the impact of Bup/Nx maintenance 
dose, pain level, and withdrawal symptoms on oxycodone self-administration. The time 
point used in our analyses was 1 hour after the first Bup/Nx dose administration in order 
to capture peak Bup/Nx effects on pain and opioid withdrawal symptoms in the absence 
of oxycodone effects.  
In addition, as we selected only individuals who completed the 7-week inpatient 
laboratory period, we compared participants who had complete data for the outcomes of 
interest to those who did not in order to confirm the absence of a selection bias. 
The first analysis consisted of assessing the effectiveness of Bup/Nx on pain perception 
comparing the MPQ score at baseline before Bup/Nx initiation and at each laboratory 
session under the different Bup/Nx maintenance doses. We performed a bivariate 
analysis between MPQ score at baseline and MPQ score under each Bup/Nx 
maintenance dose using a generalized estimating equations (GEE) model to take into 
account the intra-individual correlation for pain measurements under Bup/Nx 
maintenance. In addition, we used a linear regression model based on GEE to assess 
the association between MPQ pain score and Bup/Nx maintenance doses. 
Next, we confirmed the results of our previous paper [17] comparing the reinforcing 
effect of oxycodone among the different dosing conditions (Bup/Nx and oxycodone) 
using a repeated-measures ANOVA with a significance level of alpha at 0.05. A Mann-
Whitney test was performed to compare the difference between percent drug choice for 
placebo and each active oxycodone dose condition: placebo versus 10, 20, 40 and 60 
mg. 
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To investigate the risk of oxycodone self-administration, we generated a variable called 
“oxycodone preference,” defined as self-administration of 60% or more of the dose of 
oxycodone during the choice sessions. Then we used a logit model based on 
generalized estimating equations (GEE) [40] to identify variables associated with 
oxycodone preference. This approach was used in order to study factors associated with 
oxycodone preference during laboratory sessions, while taking into account the 
correlation between repeated measures on the same individuals [3]. We used an 
unstructured covariance matrix to model the correlation between the repeated 
measures. Variables with p-values <0.20 in the bivariate analysis were considered 
eligible for the final model, which was built using a backward procedure based on the 
log-likelihood ratio-test.  
In addition, we assessed the association between the two variables that have pain 
dimensions, the pain score and the withdrawal score measured respectively with the 
MPQ and the SOWS, and also their possible interaction with oxycodone self-
administration. Then, we performed two separate multivariate models to identify factors 
associated with “oxycodone preference” using first MPQ score and then SOWS score as 
explanatory variables. 
All of the analyses were performed using SPSS version 18.0 (SPSS Inc, Chicago, IL, 
USA) and Stata version 10.1 (Stata Corp, Texas, USA) for Windows software packages. 
Results 
During the enrollment phase of the study, 191 individuals were assessed for eligibility 
and 140 were excluded because they did not meet the inclusion criteria (N=78; medical 
rule out (N=21), psychiatric rule out (N=10), not opioid abusing/dependent (N=29), other 
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substance dependence (N=13), or other (N=5)) or lost to follow-up (N=62). Of the 51 
who were randomized to the trial, 8 discontinued prior to the inpatient phase (medical 
drop (N=2), not interested in treatment (N=5) and lost to follow-up (N=1)). Among the 43 
participants who entered the inpatient study, 12 dropped before the end of the study (2 
for medical reasons, 2 for non-compliance, 7 for self-withdrawal and 1 for another 
reason). Of the 31 participants who completed the 7-week inpatient laboratory period, 6 
participants completed a pilot phase during which a different oxycodone dose range was 
tested, so we only used data from the remaining 25 participants for our analyses. The 
participants who were selected for the analyses were similar to the others who were 
excluded regarding all the socio-demographic variables. Data from a total of 25 
participants were used in the analyses, accounting for 375 observations. Of the 25 
participants selected for the analyses, the median [interquartile range (IQR)] age was 48 
(43–54) years and 9 (36%) were women. Nine (36%) of the participants were African 
American, 8 (32%) were Hispanic and 8 (32%) were Caucasian. Reasons for study 
discontinuation among the 18 participants who did not complete the 7-week study were: 
psychiatric issues (2), intolerance to environment (2), intolerance to Bup/Nx (2 for 
nausea and 1 for heavy sedation), behavioral issues (5), seeking treatment (1) and lost 
to follow-up (5). 
The median [IQR] duration of PO use was 5 [2-8] years. Prescription opioids that were 
used during screening included mainly oxycodone, hydrocodone, hydromorphone and 
tramadol. The median [IQR] number of pills used per day was 7 [4-10], corresponding to 
60 [38-144] mg of morphine equivalents (Table 1).  At the screening visit, 9 (36%) of the 
participants had urine samples positive for cocaine. Only one participant reported using 
heroin during the previous month. Among the 21 participants who completed the McGill 
Pain Questionnaire at baseline, the median [IQR] pain score at the screening visit was 
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38 [30-50]. The median [IQR] MPQ score under Bup/Nx maintenance for the 25 
participants accounting for 375 timepoints was 21 [15-31]. MPQ score significantly 
decreased between baseline and laboratory sessions (coefficient [95% CI] =-15.88 [-
18.67,-13.10], p<0.001), suggesting that Bup/Nx had a positive impact on pain score 
relative to pre-study pain ratings. Moreover, compared to 2 mg Bup/Nx, 8 mg Bup/Nx 
significantly decreased MPQ pain score [OR (95%CI)= -1.68 (-3.15 ; -0.21); P=0.03] and 
even more under the 16 mg Bup/Nx dose condition [OR (95%CI)= -2.74 (-4.21 ; -1.27); 
P<0.001]. 
Consistent with our previous paper [17], oxycodone was not self-administered above 
placebo levels at any dose tested nor did it vary as a function of Bup/Nx maintenance 
dose condition (Figure 2). Mann-Whitney tests revealed no significant differences 
(p>0.05) between oxycodone placebo and active oxycodone doses under the 3 Bup/Nx 
doses (2/0.5, 8/2 and 16/4 mg). Although oxycodone produced minimal reinforcing 
effects overall, during 41 (11%) of the sessions, participants chose more than 60% of the 
available dose of oxycodone, accounting for 9 (36%) participants. Withdrawal symptoms 
were reported in 307 (83%) sessions with a median [IQR] score of 4 [1-9] out of a 
maximum possible score of 64.  
The results of the bivariate analysis are presented in Table 1. We excluded from the 
analyses the variables found in fewer than 10% of the „participants‟ such as self-reported 
heroin use (1 participant), self-reported cannabis use (1 participant), positive cannabis 
toxicology (2 participants), and positive methadone toxicology (2 participants). The 
variables eligible for the final model are indicated in bold type in Table 1. Some baseline 
variables were found to be associated with oxycodone „preference‟ such as being 
Caucasian, reporting use of a higher number of PO pills per day, using more morphine 
equivalents per day, and having a urine sample positive for benzodiazepines at the 
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baseline interview. Focusing on the laboratory session dependent variables, the results 
showed that the highest Bup/Nx maintenance dose (16/4 mg) was associated with less 
oxycodone preference. Furthermore, higher pain scores using the MPQ were associated 
with greater oxycodone preference. In addition, higher total SOWS scores were 
associated with oxycodone preference. 
The results presented in Table 2 show two different models after multiple adjustments, 
one including a withdrawal symptoms variable and the other a pain variable. Both tables, 
Table 2a and Table 2b, show that two variables remained associated with oxycodone 
preference, Bup/Nx dose and withdrawal/pain variable. When participants were 
maintained on the highest dose of Bup/Nx (16/4 mg), they had a two-fold lower risk of 
preferring oxycodone. Furthermore, those who reported more withdrawal symptoms [OR 
(95%CI) = 1.96 [1.29-3.00]; P=0.002] and those who had higher pain scores [OR 
(95%CI)=1.59 [1.15-2.20]; P=0.005] were more likely to self-administer oxycodone. 
Interestingly, the number of morphine equivalents used per day at baseline did not 
remain significantly associated with the outcome. No significant interaction was found 
between MPQ pain score and SOWS score regarding oxycodone preference (P=0.44). 
However, we found a significant association between MPQ pain score and SOWS score 
[OR (95%CI)=0.85 (0.63-1.07); P<0.001]. 
 
Discussion 
Overall, the data indicate that Bup/Nx-maintained opioid-dependent patients with pain do 
not robustly self-administer oxycodone, as described in our previous article [17]. This 
result is consistent with the conclusions drawn in a major article on buprenorphine 
pharmacology showing that the effects of morphine, a full mu-receptor selective opioid 
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agonist similar to oxycodone [30], were significantly attenuated when given to 
participants during the time of chronic buprenorphine administration [14]. 
In addition, Bup/Nx maintenance showed a positive impact on pain in our participants, 
with greater analgesic effects under maintenance on higher doses of Bup/Nx, especially 
with 16/4 mg. These findings are of great interest because they demonstrate the 
potential utility of Bup/Nx for treating pain in populations who also abuse prescription 
opioids. Indeed, buprenorphine is known as an effective opioid maintenance treatment 
for opioid dependence and studies have previously shown that buprenorphine is 
effective in relieving pain in non-dependent and opioid-dependent individuals under 
certain conditions. For example, a recent randomized study in adults with acute pain 
showed that sublingual buprenorphine is as effective at reducing pain as intravenous 
morphine [13]. In a sample of opioid-naive patients with chronic back pain, another 
randomized trial demonstrated the efficacy of transdermal buprenorphine in reducing 
pain [34]. Another article reviewed the treatment options for opioid dependence and pain 
and mentioned the possibility of using the partial mu-agonist buprenorphine in the 
management of concurrent pain and opioid addiction [23]. In addition, a recent 
randomized study showed that in patients with chronic pain, there is a similar analgesic 
and tolerability profile when patients are converted from hydrocodone/acetaminophen 
(Vicodin®) to transdermal buprenorphine [31]. Finally, a retrospective study reported 
positive results in pain reduction with Bup/Nx to treat co-occurring chronic non-cancer 
pain and opioid dependence in a primary care setting [28]. Data from our study suggest 
that among patients with co-occurring pain and opioid abuse, higher doses of 
buprenorphine are more effective than lower doses for simultaneously controlling both 
pain and opioid abuse.   
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To present our findings in a more “public health” approach, we performed further 
analyses regarding oxycodone preference. Although our findings suggest that 
buprenorphine may be effective in reducing the reinforcing effects of oxycodone among 
patients with chronic pain who abuse their prescription opioids, an in-depth analysis of 
the correlates of preference for oxycodone under buprenorphine/naloxone maintenance 
seemed to be important to identify some potential factors associated with the abuse 
liability of oxycodone in this population. After adjusting the model aimed at identifying 
factors associated with oxycodone preference, no variable related to participant baseline 
characteristics remained associated with oxycodone preference. It is interesting to note 
that participants who reported using a higher number of morphine equivalents before 
entering the study were not more likely to self-administer oxycodone. This result 
suggests that Bup/Nx is effective in reducing the abuse liability of oxycodone regardless 
of level of PO use. However, caution is required because our participants were selected 
according to specific inclusion criteria that could have selected less heavy PO users.  
 
It is known that specific sub-populations might be at risk of abusing prescription opioids 
such as oxycodone [29]. Our bivariate analysis showed that benzodiazepine users, 
cannabis users, and those who endorsed using heroin at baseline were more likely to 
self-administer oxycodone. These findings highlight the importance of identifying patients 
at higher risk of opioid misuse or addiction as recommended by the Canadian guideline 
for safe and effective use of opioids for chronic pain [19], as well as circumstances under 
which opioid misuse is more likely. Interestingly, the variables that remained associated 
with the oxycodone self-administration were pain score, withdrawal symptoms, and 
Bup/Nx dose. The results suggested that pain assessment remains a key component to 
adapt the pharmacological treatment. In this study, higher pain scores and higher 
withdrawal symptoms scores were associated with more oxycodone self-administration. 
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It has been shown previously that non-medical use of PO was associated with bodily 
pain in a population of injecting drug users [21]. Moreover, withdrawal symptoms have 
been found to be a predictor of non-medical use of opioids during opioid maintenance 
treatment [32]. Our results highlight the difficulty in differentiating pain from withdrawal 
and from a chronic pain condition. For this reason, several studies have noted the 
importance of including opioid withdrawal assessments in the management of pain, 
especially in an opioid-dependent population [35, 37].  
 
In addition, our findings showed that buprenorphine maintenance dose could play a role 
in oxycodone preference. It is known that suboptimal doses of buprenorphine may have 
negative consequences on treatment efficacy [24]. Because dose adjustment depends 
on multiple pharmacokinetic and pharmacodynamic parameters, characterized by inter-
individual differences, it is crucial to measure patient perceptions regarding the 
effectiveness of buprenorphine in alleviating withdrawal symptoms and pain. One 
strategy for treating chronic pain is to administer opioid doses in an escalating manner. 
Naliboff and colleagues used this method and showed some improvements in self-
reported acute relief from pain without an increase in supplemental opioid use compared 
to a stable dose strategy [27]. Previous studies have shown that the analgesic effects of 
buprenorphine could be improved by increasing the dose or by prescribing daily divided 
doses [22] and that doses of 32 mg or higher could be safe and effective [15]. Indeed, 
the therapeutic choice of using a partial mu-agonist medication is known to reduce the 
risk of overdoses compared to other full agonist analgesics [4]. A previous study showed 
that buprenorphine causes limited respiratory depression with a ceiling effect at higher 
dose [6]. 
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Although use of a within-subjects, repeated-measures design in participants housed on 
an inpatient research unit is strong experimentally, some limitations also must be 
acknowledged. First, the participants we enrolled had to fulfill several inclusion and 
exclusion criteria, which may have reduced the external validity of the results. Indeed, 
our sample excluded the most severely opioid dependent individuals and those with 
certain types of pain (e.g., those with neuropathic pain, multiple failed back surgeries, as 
well as those with a previous lack of analgesic response to buprenorphine). Thus, further 
studies are needed in opioid dependent individuals with other types of pain and a more 
complex addictive profile. Moreover, the highest dose we tested (16 mg) may be 
considered as inadequate for some patients and may need to be increased to manage 
both pain and opioid dependence. Also, because oxycodone is commonly abused by the 
intranasal or intravenous routes, future studies should test higher doses of Bup/Nx in 
combination with opioid agonists administered by non-oral routes. Finally, the context of 
laboratory sessions is different from the ecological context of the participants‟ lives. 
Therefore, a clinical trial conducted on an outpatient basis and/or an epidemiological 
study would be appropriate to confirm the present results [36].  
Nevertheless, our data suggest that buprenorphine could be an effective medication for 
those patients who need to be treated for chronic pain and opioid abuse/dependence. 
Further studies should be implemented to determine the profile of pain patients most 
likely to abuse prescription opioids. 
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